ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common ...
ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...
ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in ...
ImmunityBio (IBRX) stock was up 15% Thursday, the day after it issued updates on its regulatory submissions in the United ...
The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ...
4don MSN
We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code assigned by the Centers for Medicare & ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback